Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Ned Tijdschr Geneeskd ; 159: A8875, 2015.
Artigo em Holandês | MEDLINE | ID: mdl-26013253

RESUMO

Familial hypercholesterolemia (FH) is a monogenic autosomal dominant disorder. FH is the most common hereditary cause of raised serum cholesterol levels and is associated with an increased risk of premature cardiovascular disease (CVD). This disorder is known to have a genetic cause, and effective drug therapies exist for patients with FH. Successful cascade screening, within the framework of a national screening programme, gave the Netherlands an international role as model and pioneer as far as FH detection is concerned. With the ending of this screening programme as of 1 January 2014 the care for FH patients, including screening and counselling has had to be incorporated within the basic Dutch healthcare insurance system. It is essential that detection of FH should continue in as efficient and cost-effective a manner as possible. Our proposal is that this detection should be performed and co-ordinated by those treating patients with FH so that FH screening, counselling and treatment are integrated.


Assuntos
Aconselhamento , Hiperlipoproteinemia Tipo II/diagnóstico , Programas de Rastreamento/métodos , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/prevenção & controle , Colesterol/sangue , Análise Custo-Benefício , Prestação Integrada de Cuidados de Saúde , Terapia Genética , Humanos , Hiperlipoproteinemia Tipo II/complicações , Hiperlipoproteinemia Tipo II/genética , Hiperlipoproteinemia Tipo II/terapia , Programas de Rastreamento/economia , Países Baixos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA